Preliminary results of the Alzheimer’s management by albumin replacement (AMBAR) study show improvements in short-term verbal memory, language fluency, and processing speed in mild–moderate AD patients who underwent plasma exchange [45], but more evidence is needed to assess its replicability and the feasibility of large-scale implementation. Here, ALB is linked to Alzheimer disease.